BioSpace News Archive

Nurix will utilize its proprietary drug discovery platform, DELigase™, that integrates its DNA-encoded libraries and its unparalleled portfolio of E3 ligases to create small molecules designed to induce degradation of three specified drug targets, with an option by Sanofi to expand to a total of five targets.

Today IAVI, a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges, announces the launch of IAVI DataSpace, an open-access, online portal to a one-of-a-kind dataset from a study of early HIV infection in a unique sub-Saharan African cohort.

BioProtect ltd., a private company developing unique bioabsorbable polymer spacer balloons, announced the initial closing of $13 million of its Series D equity financing from a leading global syndicate of venture investors.

MBio Diagnostics today announced two contracts with SRI International to develop tests related to homeland security on the MBio Diagnostics platform technology.

TriAltus Bioscience, LLC, transforming protein-based research, announced its participation and poster presentation at the 19th annual PepTalk: The Protein Science Week.

Civica Rx (Civica, Inc.) today announced that it is interested in talking to generic drug manufacturers who are considering retiring or withdrawing their Abbreviated New Drug Applications (ANDAs) for essential medicines that are at risk of being in short supply

Heska Corporation, a provider of advanced veterinary diagnostic and specialty products, announced that the Company has entered into an agreement to acquire 100% of the capital stock of scil animal care company GmbH from Covetrus, Inc.

ASKA Pharmaceutical Co., Ltd. and KinoPharma, Inc., both based in Tokyo, announced on January 14 that they have entered into an option agreement for an exclusive license for the development and commercialization of a candidate drug for cervical dysplasia under preclinical development by KinoPharma..

Ipsen announced the appointment of Dr. Steven Hildemann as Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance effective March 1, 2020.

TAI Diagnostics, Inc. announced the publication of “Cell-Free DNA Donor Fraction Analysis in Pediatric and Adult Heart Transplant Patients by Multiplexed Allele-Specific Quantitative PCR: Validation of a Rapid and Highly Sensitive Clinical Test for Stratification of Rejection Probability“ in the January 13, 2020 issue of the journal, PLOS ONE.